Literature DB >> 25831242

Stereotactic body radiotherapy for oligometastases confined to the para-aortic region: clinical outcomes and the significance of radiotherapy field and dose.

Young-Seok Seo1, Mi-Sook Kim, Chul-Koo Cho, Hyung-Jun Yoo, Won-Il Jang, Kum-Bae Kim, Dong-Han Lee, Sun-Mi Moon, Hoy-Rak Lee.   

Abstract

We retrospectively reviewed 88 patients with oligometases in the para-aortic region from any controlled primary tumor site who were treated with stereotactic body radiotherapy (SBRT). The 5-year local control, disease-free survival, and overall survival rates were 83%, 31%, and 41%, respectively. A 90% tumor-control probability was predicted at a biological effective dose of 90 Gy. Severe gastrointestinal toxicities (grade ≥3) were observed in 2 of 88 patients (1%). The results of this study are limited by the retrospective nature of the study but could serve as the background and rationale for future prospective trials on SBRT-based treatment for oligometastses.

Entities:  

Keywords:  Outcomes research; Prognosis and response predictions; Radiation oncology

Mesh:

Year:  2015        PMID: 25831242     DOI: 10.3109/07357907.2015.1019678

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  6 in total

1.  Systematic review of stereotactic body radiotherapy for nodal metastases.

Authors:  Francesco Deodato; Gabriella Macchia; Milly Buwenge; Mattia Bonetti; Savino Cilla; Alice Zamagni; Alessia Re; Donato Pezzulla; Francesco Cellini; Lidia Strigari; Vincenzo Valentini; Alessio G Morganti
Journal:  Clin Exp Metastasis       Date:  2021-01-16       Impact factor: 5.150

2.  Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis.

Authors:  Kelsey L Corrigan; Alison Yoder; Brian De; Lilie Lin; Anuja Jhingran; Melissa M Joyner; Patricia J Eifel; Lauren E Colbert; Karen H Lu; Ann H Klopp
Journal:  Gynecol Oncol       Date:  2021-12-30       Impact factor: 5.304

3.  Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy.

Authors:  E Leung; A Gladwish; A Sahgal; S S Lo; C A Kunos; R M Lanciano; C A Mantz; M Guckenberger; T M Zagar; N A Mayr; A R Chang; S Jorcano; T Biswas; A Pontoriero; K V Albuquerque
Journal:  Radiat Oncol       Date:  2020-01-30       Impact factor: 3.481

4.  CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report.

Authors:  Federica Medici; Giambattista Siepe; Lidia Strigari; Francesco Massari; Milly Buwenge; Silvia Bisello; Paolo Castellucci; Stefano Fanti; Silvia Cammelli; Alessio Giuseppe Morganti
Journal:  Mol Clin Oncol       Date:  2022-02-18

Review 5.  Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer.

Authors:  Akshay Mangaj; Supriya Chopra; Remi A Nout
Journal:  Indian J Med Res       Date:  2021-08       Impact factor: 5.274

6.  Feasibility of split-course stereotactic ablative radiotherapy for oligometastases.

Authors:  Eun Kyung Paik; Mi-Sook Kim; Young-Seok Seo; Won Il Jang; Jin-Kyu Kang; Chul-Koo Cho; Hyung Jun Yoo
Journal:  Jpn J Clin Oncol       Date:  2018-06-01       Impact factor: 3.019

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.